This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (63)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Use of Bemegride (Megimide) and Hemodialysis

GEORGE E. SCHREINER, M.D.; LEONARD B. BERMAN, M.D.; RENATO KOVACH, M.D.; H. ALLAN BLOOMER, M.D.

AMA Arch Intern Med. 1958;101(5):899-911.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Glutethimide (Doriden)* has had an unusually rapid and widespread introduction into clinical medicine as a hypnotic and sedative. Chemically, glutethimide is -ethyl--phenylglutarimide whose structual formula is depicted in Figure 1. It is a white crystalline compound with a melting point of 83-85 C and a molecular weight of 217.3. It is

Fig. 1.

—Chemical structures of glutethimide (Doriden, -ethyl--phenylglutarimide) phenobarbital, and bemegride (Megimide, β-methyl-β-ethylglutarimide). very poorly soluble in water but highly soluble in alcohol and acetone. In large doses, the gastric absorption may be irregular and produce variations in the LD₅₀ obtained after oral administration in animals (0.6 gm. per kilogram in the rat and rabbit, 0.5 gm. per kilogram in the dog, and 0.15 gm. per kilogram in the mouse). The problem of absorption also makes it difficult to establish dose-toxicity relationships in human glutethimide poisoning. Once absorbed, glutethimide is eventually excreted in the bile, and up to . . . [Full Text PDF of this Article]

Author Affiliations
Washington, D. C.

From the Department of Medicine and the Renal Laboratory, Georgetown University Medical Center. Assistant Professor of Medicine, Director, Renal Clinic (Dr. Schreiner); Instructor in Medicine and Postgraduate Fellow, National Heart Institute (Berman); Clinical Fellow, Renal Laboratory (Dr. Kovach and Dr. Bloomer).

Footnotes
Submitted for publication July 16, 1957.

Presented in part at the Eastern Section, American Federation for Clinical Research, Baltimore, December, 1956.

This work was aided by grants from The Hartford Foundation, the National Institutes of Health, and the Georgetown University Kidney Research Fund.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?